Reta 20mg

Retatrutide, also known by its development code LY3437943, is a synthetic peptide developed by Eli Lilly. It is unique because it simultaneously activates three hormone receptors: GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon (GCG). This triple agonism helps regulate appetite, enhance satiety, increase energy expenditure, and improve fat metabolism, making it a promising candidate for obesity and type 2 diabetes management